The study is divided into two stages. In the first stage, researchers will determine the best dosing schedule for the eye drops. In the second stage, they will compare the effects of the eye drops to a placebo over a period of 52 weeks. Participants will be randomly assigned to receive either the OCS-01 eye drops or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a “double-masked” study, which helps ensure that the results are unbiased.

Throughout the study, participants will have regular check-ups to monitor their eye health and vision. The main focus will be on changes in vision clarity, measured by a test called Best Corrected Visual Acuity (BCVA). This test helps determine how well a person can see with the best possible glasses or contact lenses. The study aims to see if the OCS-01 eye drops can improve vision in people with DME compared to those who receive a placebo. Participants will also be monitored for any side effects or safety concerns related to the treatment.

Participants in the study will be assigned to receive either the test medication or the comparison medication. The process involves monitoring changes in best corrected visual acuity, which refers to how clearly a person can see when wearing glasses or contact lenses. The study will observe how these treatments affect the thickness of the retina and how frequently eye treatments are required over a set period of time.

During the study, participants will receive either the new implant or the standard injection. The process involves monitoring changes in best corrected visual acuity, which refers to the clearest vision a person can achieve with glasses or contact lenses. Researchers will also observe changes in the thickness of the retina and how well participants can read letters on an eye chart over a period of time. The study will track how often additional treatments are required and how the swelling in the eye responds to the different options provided.

During the study, participants will receive either AVT29 or a high dose of Eylea. The medical team will monitor changes in best-corrected visual acuity, which refers to the clearest vision possible with glasses or contact lenses. Additionally, the study will look at changes in central subfield thickness, a measurement of how much the middle part of the retina has thickened due to swelling, and the presence of intraretinal fluid, which is liquid trapped inside the layers of the retina. Regular check-ups will also be performed to monitor intraocular pressure, the fluid pressure inside the eye, and other general health factors to ensure safety throughout the process.

The main purpose of this study is to determine how well faricimab improves vision in patients with diabetic macular edema over a 12-month period. The study will measure improvements in vision using specialized eye tests and examine changes in the blood vessels of the eye. The medication will be administered through eye injections, with the frequency of treatments varying between every 4, 8, 12, or 16 weeks, depending on how each patient responds to the treatment.

During the study, participants will receive Vabysmo injections containing 120 mg/mL of the medication. The treatment period lasts for 12 months, during which patients will have regular eye examinations to monitor their vision and the condition of their eyes. Various advanced imaging techniques will be used to examine the detailed structure of the eye and measure how well the treatment is working.

The purpose of this research is to understand how different doses of BI 1815368 affect vision improvement in people who have varying levels of vision problems due to diabetic macular edema. The study will compare the new medication to placebo over a treatment period of 48 weeks.

During the study, participants will take tablets by mouth and have their vision regularly checked. The research team will monitor how well participants can see using standard eye tests and measure the thickness of the retina using special imaging equipment. They will also keep track of any effects that might be related to the treatment to ensure participant safety throughout the study period.

The purpose of the study is to evaluate whether EYE103 is as effective as ranibizumab in improving vision in people with Diabetic Macular Edema. Participants in the study will receive either EYE103 or ranibizumab over a period of time, and their vision will be monitored to see how it changes. The study will last for about a year, with regular check-ups to assess the effects of the treatment.

During the study, participants will have their vision tested using a standardized chart called the ETDRS chart, which helps measure changes in vision clarity. The study aims to determine if EYE103 can provide similar benefits to ranibizumab in terms of improving vision over the course of the study. This research is important for finding effective treatments for people with Diabetic Macular Edema and improving their quality of life.

Participants in the study will receive injections of aflibercept in both eyes. The study will monitor the levels of the medication in the blood to see how it is absorbed and processed by the body. This will help researchers understand the effects of the medication when used in higher doses. The study will also include a comparison with a placebo to evaluate the effectiveness of the treatment.

The study will take place over a period of time, during which participants will receive regular injections and have their blood levels checked. This will help determine the maximum concentration of aflibercept in the blood. The information gathered from this study will contribute to understanding the safety and effectiveness of using high-dose aflibercept for treating these eye conditions.

The purpose of the study is to compare the effects of OCS-01 with a placebo over a period of 52 weeks. Participants will be randomly assigned to receive either the OCS-01 eye drops or a placebo. Throughout the study, participants will have regular check-ups to monitor their eye health and overall well-being. The main goal is to see if there is an improvement in vision, specifically looking at changes in the ability to see clearly, which is measured by a test called Best Corrected Visual Acuity (BCVA).

Participants will also be monitored for any side effects or changes in their eye condition. The study aims to provide valuable information on whether OCS-01 can be a safe and effective treatment option for people with Diabetic Macular Edema. This research could potentially lead to better management of this eye condition, improving the quality of life for those affected by it.

The purpose of the study is to evaluate the cost-effectiveness of these treatments over a period of three years. Participants will receive either the ILUVIEN or OZURDEX implant and will be monitored regularly to assess their vision and eye health. The study will also look at the overall impact of these treatments on quality of life and healthcare costs.

Throughout the study, participants will have follow-up visits to check their vision and eye condition. The study aims to provide valuable information on which treatment may be more beneficial for patients with resistant DME, helping to guide future treatment decisions. A placebo will not be used in this study.

The purpose of this study is to ensure that the AVT06 pre-filled syringe is handled correctly and safely, and to evaluate the safety of the treatment when injected into the eye. Participants in the study will receive the treatment through an injection into the eye, known as intravitreal use. The study will follow participants over a period to monitor the safety and effectiveness of the treatment. There is also an optional extension phase for further observation.

Throughout the study, the focus will be on the successful administration of the treatment and monitoring any side effects related to the eye. The study aims to provide valuable information on the safe use of Aflibercept in treating these eye conditions, helping to improve treatment options for patients with these diseases.

The purpose of the study is to compare the safety, tolerability, and effectiveness of these two treatments in people with DME. Participants in the study will be randomly assigned to receive either the OXU-001 treatment or the OZURDEX treatment. The study will be conducted over a period of time, and participants will have regular check-ups to monitor their eye health and any side effects they may experience. The study aims to determine which treatment provides better results in terms of reducing the swelling in the eye caused by DME and improving vision.

Throughout the study, participants will be closely monitored for any adverse effects related to the treatments or the devices used. The study will also assess how long the effects of the treatments last and how often additional treatments are needed. By the end of the study, researchers hope to gather valuable information that could lead to improved treatment options for people with Diabetic Macular Edema.

Participants in the study will receive either EYE103 or Ranibizumab, or a placebo, over a period of time. The study will last for about a year, during which participants will have regular check-ups to monitor their vision and overall eye health. The main goal is to measure changes in vision using a special eye chart designed for people with diabetic eye conditions. This will help determine if EYE103 can maintain or improve vision as effectively as the current treatment.

In addition to EYE103 and Ranibizumab, a substance called Fluorescein Sodium may be used during the study. This is a type of contrast agent that helps doctors see the blood vessels in the eye more clearly during examinations. The study aims to provide valuable information about the safety and effectiveness of EYE103 for people with Diabetic Macular Edema, potentially offering a new option for managing this condition.